250 related articles for article (PubMed ID: 28797519)
1. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.
Ricciardi MR; Mirabilii S; Licchetta R; Piedimonte M; Tafuri A
Adv Biol Regul; 2017 Aug; 65():36-58. PubMed ID: 28549531
[TBL] [Abstract][Full Text] [Related]
4. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
Miyamoto K; Minami Y
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
6. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
7. Coordinate PI3K pathway and Bcl-2 family disruption in AML.
Bose P; Rahmani M; Grant S
Oncotarget; 2012 Dec; 3(12):1499-500. PubMed ID: 23439314
[No Abstract] [Full Text] [Related]
8. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
9. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
10. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
[TBL] [Abstract][Full Text] [Related]
11. Personalized therapy for acute myeloid leukemia.
Hourigan CS; Karp JE
Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
Kurtz SE; Eide CA; Kaempf A; Mori M; Tognon CE; Borate U; Druker BJ; Tyner JW
Leukemia; 2018 Sep; 32(9):2025-2028. PubMed ID: 30082821
[No Abstract] [Full Text] [Related]
13. BH3 Mimetics in AML Therapy: Death and Beyond?
Cerella C; Dicato M; Diederich M
Trends Pharmacol Sci; 2020 Nov; 41(11):793-814. PubMed ID: 33032835
[TBL] [Abstract][Full Text] [Related]
14. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
15. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
Pollyea DA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.
Reikvam H; Hauge M; Brenner AK; Hatfield KJ; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):299-313. PubMed ID: 25835070
[TBL] [Abstract][Full Text] [Related]
18. Novel Treatment Paradigms in Acute Myeloid Leukemia.
Khanal N; Upadhyay Banskota S; Bhatt VR
Clin Pharmacol Ther; 2020 Sep; 108(3):506-514. PubMed ID: 32572947
[TBL] [Abstract][Full Text] [Related]
19. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
